Alnylam Pharmaceuticals
ALNY
#649
Rank
A$54.20 B
Marketcap
A$405.96
Share price
0.68%
Change (1 day)
-2.80%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): A$1.29 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$4.28 Billion. In 2025 the company made an earning of A$0.87 Billion, an increase over its 2024 earnings that were of -A$0.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.29 B46.94%
2025 A$0.87 B-369.48%
2024 -A$0.33 Billion-24.59%
2023 -A$0.44 Billion-67.84%
2022 -A$1.35 Billion36.93%
2021 -A$0.99 Billion-8.04%
2020 -A$1.07 Billion-15.66%
2019 -A$1.27 Billion12.23%
2018 -A$1.13 Billion62.91%
2017 -A$0.7 Billion17.78%
2016 -A$0.59 Billion43.44%
2015 -A$0.41 Billion60.69%
2014 -A$0.26 Billion98.2%
2013 -A$0.13 Billion
2011 -A$75.84 Million27.48%
2010 -A$59.49 Million-10.92%
2009 -A$66.78 Million95.77%
2008 -A$34.12 Million
2006 -A$54.65 Million-9.13%
2005 -A$60.14 Million34.74%
2004 -A$44.64 Million36.79%
2003 -A$32.63 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$21.83 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$10.59 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.13 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.98 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$65.62 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.23 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$3.14 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.47 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA